Skip to main content
Erschienen in: Psychiatric Quarterly 4/2020

13.05.2020 | Original Paper

Sociodemographic Factors and Medication Administration Factors Affecting Re – Hospitalization in Patients with Schizophrenia – Spectrum Disorders

verfasst von: Serafeim Papakostas, Ayesha Dar, Lawrence Ratna

Erschienen in: Psychiatric Quarterly | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Schizophrenia – spectrum disorders have been shown to have large economic costs for the society due to hospitalizations. Long Acting Injections (LAIs) have been shown to promote adherence and reduce hospitalizations. However, socio-demographic and environmental variables have been shown to be associated with relapses. The present study attempted to explore relationships between rehospitalisation and such variables by analysing data from the Attitudes Study. Our findings validate previous literature on LAIs showing a larger effect of route of drug administration on hospitalizations. However, our study also highlights the importance of living circumstances and ethnicity that were shown to have an effect on hospitalizations and explained a larger part of the variance when it came to furthers hospitalisations. Furthermore, associations of variables relating to disease history with variables like gender, education and employment are presented highlighting the importance of a multi-approach model when it comes to preventing future hospitalizations.
Literatur
1.
Zurück zum Zitat Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800 Available from. https://doi.org/10.1016/S0140-6736(15)60692-4.CrossRef Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800 Available from. https://​doi.​org/​10.​1016/​S0140-6736(15)60692-4.CrossRef
2.
Zurück zum Zitat Robinson D, Woerner M, Alvir J, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241–7.CrossRef Robinson D, Woerner M, Alvir J, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241–7.CrossRef
3.
Zurück zum Zitat National Healthcare system of England. Inpatients formally detained in hospitals under the Mental Health Act 1983 and patients subject to Supervised Community Treatment: 2015/16, Annual figures. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/inpatients-formally-detained-in-hospitals-under-the-mental-health-act-1983-and-patients-subject-to-supervised-community-treatment/inpatients-formally-detained-in-hospitals-under-the-mental-health-act-1983-and-patients-subject-to-supervised-community-treatment-2015-16-annual-figures [Accessed 16th June, 2019]. National Healthcare system of England. Inpatients formally detained in hospitals under the Mental Health Act 1983 and patients subject to Supervised Community Treatment: 2015/16, Annual figures. Available from: https://​digital.​nhs.​uk/​data-and-information/​publications/​statistical/​inpatients-formally-detained-in-hospitals-under-the-mental-health-act-1983-and-patients-subject-to-supervised-community-treatment/​inpatients-formally-detained-in-hospitals-under-the-mental-health-act-1983-and-patients-subject-to-supervised-community-treatment-2015-16-annual-figures [Accessed 16th June, 2019].
4.
Zurück zum Zitat Alvarez-Jimenez M, Parker A, Hetrick S, McGorry P, Gleeson J. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37:619–30.CrossRef Alvarez-Jimenez M, Parker A, Hetrick S, McGorry P, Gleeson J. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37:619–30.CrossRef
5.
Zurück zum Zitat Ascher-Svanum H, Zhu B, Faries D, Salkever D, Slade E, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.CrossRef Ascher-Svanum H, Zhu B, Faries D, Salkever D, Slade E, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.CrossRef
6.
Zurück zum Zitat Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou SF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–73. Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou SF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–73.
7.
Zurück zum Zitat Crossley N, Mechelli A, Fusar-Poli P, Broome M, Matthiasson P, Johns L, et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp. 2009;30:4129–37.CrossRef Crossley N, Mechelli A, Fusar-Poli P, Broome M, Matthiasson P, Johns L, et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp. 2009;30:4129–37.CrossRef
8.
Zurück zum Zitat Fusar-Poli P, Borgwardt S, Crescini A, D’Este G, Kempton M, Lawrie S, et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev. 2011a;35:1175–85.CrossRef Fusar-Poli P, Borgwardt S, Crescini A, D’Este G, Kempton M, Lawrie S, et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev. 2011a;35:1175–85.CrossRef
9.
Zurück zum Zitat Fusar-Poli P, Howes O, Allen P, Broome M, Valli I, Asselin M, et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry. 2011b;16:67–75.CrossRef Fusar-Poli P, Howes O, Allen P, Broome M, Valli I, Asselin M, et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry. 2011b;16:67–75.CrossRef
10.
Zurück zum Zitat Howes O, Montgomery A, Asselin M, Valli I, Tabraham P, Johns L, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13–20.CrossRef Howes O, Montgomery A, Asselin M, Valli I, Tabraham P, Johns L, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13–20.CrossRef
11.
Zurück zum Zitat Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat. 2015;72:334–41.CrossRef Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat. 2015;72:334–41.CrossRef
12.
Zurück zum Zitat Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741–73.CrossRef Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741–73.CrossRef
14.
Zurück zum Zitat Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of non-adherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275–84.CrossRef Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of non-adherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275–84.CrossRef
15.
Zurück zum Zitat Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83–92.CrossRef Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83–92.CrossRef
16.
Zurück zum Zitat Haddad P, Taylor M, Niaz O. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry. 2009;195(52):20–8.CrossRef Haddad P, Taylor M, Niaz O. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry. 2009;195(52):20–8.CrossRef
17.
Zurück zum Zitat Tiihonen J, Haukka J, Taylor M, Haddad P, Patel M, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatr. 2011;168:603–9.CrossRef Tiihonen J, Haukka J, Taylor M, Haddad P, Patel M, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatr. 2011;168:603–9.CrossRef
20.
Zurück zum Zitat De Risio A, Lang AP. History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol. 2014;9(1):39.CrossRef De Risio A, Lang AP. History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol. 2014;9(1):39.CrossRef
21.
Zurück zum Zitat Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231.CrossRef Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231.CrossRef
22.
Zurück zum Zitat Nuechterlein, K. H., Dawson, M. E., Ventura, J., Gitlin, M., Subotnik, K. L., Snyder, K. S., et al. The vulnerability/stress model of schizophrenic relapse: a longitudinal study, Acta Psychiatr Scand Supp, 1994; 382: 58. Nuechterlein, K. H., Dawson, M. E., Ventura, J., Gitlin, M., Subotnik, K. L., Snyder, K. S., et al. The vulnerability/stress model of schizophrenic relapse: a longitudinal study, Acta Psychiatr Scand Supp, 1994; 382: 58.
24.
33.
Zurück zum Zitat Suttajit S, Pilakanta S. Impact of depression and social support on non-adherence to antipsychotic drugs in persons with schizophrenia in Thailand. Patient Prefer Adher. 2010;4:363.CrossRef Suttajit S, Pilakanta S. Impact of depression and social support on non-adherence to antipsychotic drugs in persons with schizophrenia in Thailand. Patient Prefer Adher. 2010;4:363.CrossRef
34.
Zurück zum Zitat Xiao J, Mi W, Li L, Shi Y, Zhang H. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s republic of China. Neuropsychiatr Dis Treat, 2014; 11: 1161-1161167 Available from: https://doi.org/10.2147/NDT.S72367, Xiao J, Mi W, Li L, Shi Y, Zhang H. High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s republic of China. Neuropsychiatr Dis Treat, 2014; 11: 1161-1161167 Available from: https://​doi.​org/​10.​2147/​NDT.​S72367,
35.
Zurück zum Zitat Sariah A, Outwater A, Malima K. Risk and protective factors for relapse among individuals with schizophrenia: a qualitative study in Dar Es Salaam, Tanzania. BMC Psychiatry. 2014;14:240.CrossRef Sariah A, Outwater A, Malima K. Risk and protective factors for relapse among individuals with schizophrenia: a qualitative study in Dar Es Salaam, Tanzania. BMC Psychiatry. 2014;14:240.CrossRef
37.
Zurück zum Zitat Allardyce J, Boydell J. Review: the wider social environment and schizophrenia. Schizophr Bull. 2006;32(4):592–8.CrossRef Allardyce J, Boydell J. Review: the wider social environment and schizophrenia. Schizophr Bull. 2006;32(4):592–8.CrossRef
Metadaten
Titel
Sociodemographic Factors and Medication Administration Factors Affecting Re – Hospitalization in Patients with Schizophrenia – Spectrum Disorders
verfasst von
Serafeim Papakostas
Ayesha Dar
Lawrence Ratna
Publikationsdatum
13.05.2020
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 4/2020
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-020-09756-z

Weitere Artikel der Ausgabe 4/2020

Psychiatric Quarterly 4/2020 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.